BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 16489012)

  • 1. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
    Sato M; Vaughan MB; Girard L; Peyton M; Lee W; Shames DS; Ramirez RD; Sunaga N; Gazdar AF; Shay JW; Minna JD
    Cancer Res; 2006 Feb; 66(4):2116-28. PubMed ID: 16489012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.
    Jiang J; Greulich H; Jänne PA; Sellers WR; Meyerson M; Griffin JD
    Cancer Res; 2005 Oct; 65(19):8968-74. PubMed ID: 16204070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.
    Konishi H; Karakas B; Abukhdeir AM; Lauring J; Gustin JP; Garay JP; Konishi Y; Gallmeier E; Bachman KE; Park BH
    Cancer Res; 2007 Sep; 67(18):8460-7. PubMed ID: 17875684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins.
    Ramirez RD; Sheridan S; Girard L; Sato M; Kim Y; Pollack J; Peyton M; Zou Y; Kurie JM; Dimaio JM; Milchgrub S; Smith AL; Souza RF; Gilbey L; Zhang X; Gandia K; Vaughan MB; Wright WE; Gazdar AF; Shay JW; Minna JD
    Cancer Res; 2004 Dec; 64(24):9027-34. PubMed ID: 15604268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations.
    Sato M; Larsen JE; Lee W; Sun H; Shames DS; Dalvi MP; Ramirez RD; Tang H; DiMaio JM; Gao B; Xie Y; Wistuba II; Gazdar AF; Shay JW; Minna JD
    Mol Cancer Res; 2013 Jun; 11(6):638-50. PubMed ID: 23449933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells.
    Akca H; Tani M; Hishida T; Matsumoto S; Yokota J
    Lung Cancer; 2006 Oct; 54(1):25-33. PubMed ID: 16872715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression.
    Guerrero S; Casanova I; Farré L; Mazo A; Capellà G; Mangues R
    Cancer Res; 2000 Dec; 60(23):6750-6. PubMed ID: 11118062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. K-RAS(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs.
    Minjgee M; Toulany M; Kehlbach R; Giehl K; Rodemann HP
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1506-14. PubMed ID: 21985943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.
    Alvarez JV; Greulich H; Sellers WR; Meyerson M; Frank DA
    Cancer Res; 2006 Mar; 66(6):3162-8. PubMed ID: 16540667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to mutant KRAS
    Muraki N; Yamada M; Doki H; Nakai R; Komeda K; Goto D; Kawabe N; Matsuoka K; Matsushima M; Kawabe T; Tanaka I; Morise M; Shay JW; Minna JD; Sato M
    Exp Cell Res; 2022 May; 414(1):113053. PubMed ID: 35149086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras.
    Kim SH; Nakagawa H; Navaraj A; Naomoto Y; Klein-Szanto AJ; Rustgi AK; El-Deiry WS
    Cancer Res; 2006 Nov; 66(21):10415-24. PubMed ID: 17079462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stepwise neoplastic transformation of a telomerase immortalized fibroblast cell line.
    Zongaro S; de Stanchina E; Colombo T; D'Incalci M; Giulotto E; Mondello C
    Cancer Res; 2005 Dec; 65(24):11411-8. PubMed ID: 16357149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation.
    Ciardiello F; McGeady ML; Kim N; Basolo F; Hynes N; Langton BC; Yokozaki H; Saeki T; Elliott JW; Masui H
    Cell Growth Differ; 1990 Sep; 1(9):407-20. PubMed ID: 1981145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3.
    Leslie K; Lang C; Devgan G; Azare J; Berishaj M; Gerald W; Kim YB; Paz K; Darnell JE; Albanese C; Sakamaki T; Pestell R; Bromberg J
    Cancer Res; 2006 Mar; 66(5):2544-52. PubMed ID: 16510571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
    Haura EB; Zheng Z; Song L; Cantor A; Bepler G
    Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
    Sordella R; Bell DW; Haber DA; Settleman J
    Science; 2004 Aug; 305(5687):1163-7. PubMed ID: 15284455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional identification of LRF as an oncogene that bypasses RASV12-induced senescence via upregulation of CYCLIN E.
    Vredeveld LC; Rowland BD; Douma S; Bernards R; Peeper DS
    Carcinogenesis; 2010 Feb; 31(2):201-7. PubMed ID: 19942610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.